Verified peer comparison

TMO vs DHR

Thermo Fisher Scientific Inc. compared with Danaher Corporation. This page compares both source-verified company profiles and does not introduce an unverified price target.

TMO

Thermo Fisher Scientific Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

DHR

Danaher Corporation

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

TMO: Life Sciences Tools and Services

DHR: Life Sciences Tools and Services

Upside lens

TMO: Strengthening demand from pharmaceutical and biotechnology customers can improve organic growth across instruments, consumables, and biopharma services. The completed Clario acquisition expands Thermo Fisher's clinical research capabilities and creates cross-selling and productivity opportunities within biopharma services. Continued productivity initiatives can support margin expansion even while end-market recovery remains uneven.

DHR: Normalization in large-pharma and biotech ordering can restore growth in consumables and equipment. A large installed base in life sciences and diagnostics supports repeat reagent, service and consumable demand. Disciplined integration of Masimo can broaden specialty diagnostics and create operating-improvement opportunities.

Risk lens

TMO: Muted U.S. and China conditions in academic and government markets can constrain instrument and consumables demand. Slightly declining China revenue and uncertain local funding conditions could delay a broader recovery in Asia-Pacific demand. Debt increased following acquisition activity, raising integration, financing-cost, and capital-allocation risk if expected returns take longer to emerge.

DHR: Weak biotechnology funding or customer destocking could delay a sustained order recovery. Large acquisitions can bring debt, execution, regulatory and synergy-realization risk. Procurement policy, local competition and macro weakness can pressure diagnostics and life-science demand.

Verified sources

Thermo Fisher Scientific Reports First Quarter 2026 ResultsThermo Fisher Scientific Inc. · earningsVerified